Vivus, Why the Slide? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vivus, Why the Slide?

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Richard Singer who wrote (2709)	7/14/1997 8:22:00 PM
From: Frostman	of 3991

Richard, Reference the First Boston report on VVUS, post earnings: Shareholders should like the First Boston (revised) price target for VVUS of $35. I like the fact that no real competitive ED products are expected to join the market until 1999 with the assumption that these products are determined to be safe and effective. That's a serious head start for VVUS. Under the section dealing with INVESTMENT RISKS, can you please tell tell me what you think they mean by "...investors should be aware that liquidity constraints can also be a major trading hindrance." Is this boiler plate stuff or another, shudder, yawn, short interest reference? Hells bells. Keep your calculator out, big guy. I think tomorrow rounds out the "three day rule" on the earnings report. Glad I picked up some at 29 this morning. Frostman

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next